Reversible BTK Inhibitor Gets FDA Nod for Mantle Cell Lymphoma

(MedPage Today) -- The FDA has granted accelerated approval to pirtobrutinib (Jaypirca), a non-covalent or reversible Bruton's tyrosine kinase (BTK) inhibitor, for the treatment of relapsed or refractory mantle cell lymphoma (MCL) after at least...
Source: MedPage Today Public Health - Category: American Health Source Type: news